Stengone Carmine N. 4
4 · Contineum Therapeutics, Inc. · Filed Jan 31, 2025
Insider Transaction Report
Form 4
Stengone Carmine N.
DirectorCEO and President
Transactions
- Award
Stock Option (right to buy)
2025-01-31+300,000→ 300,000 totalExercise: $9.79Exp: 2035-01-30→ Class A Common Stock (300,000 underlying)
Footnotes (1)
- [F1]Options granted under the Issuer's 2024 Equity Incentive Plan. 25% of the option shares vest on January 1, 2026, and the remainder vests in equal monthly installments over the next 36 months thereafter, subject to the Reporting Person's continuous service.